Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT01068860) enrolled 246 participants across ten groups. Most participants had type 2 diabetes and were already taking one of several common diabetes medicines (metformin alone, metformin plus a sulfonylurea, metformin plus a sulfonylurea plus a thiazolidinedione, or insulin). A smaller group had "impaired glucose tolerance" — meaning their blood sugar was higher than normal but not yet at diabetes levels. Within each group, participants were randomly assigned to receive either canakinumab (a 150 mg injection) or a dummy (placebo) treatment for four weeks. The trial was primarily measuring how well the pancreas responded to a meal by releasing insulin — specifically, how much the rate of insulin release changed over the first two hours after a liquid meal test. The reported data shows that changes in the insulin secretion rate over the first two hours after the meal test (the primary measure) varied across the different treatment groups. For example, in the metformin-only group, the canakinumab group showed a change of −0.06 units compared to −0.23 units in the placebo group. In the insulin-plus-canakinumab group the change was +1.23 units, while the placebo-plus-insulin group showed −0.49 units. In the impaired glucose tolerance group, both the canakinumab (−1.50) and placebo (−1.93) groups showed a decline in this measure. The reported data also shows small changes in fasting blood sugar levels, fructosamine (a marker of average blood sugar over recent weeks), and fasting insulin levels across all groups, with the numbers varying in direction and size between groups. No single consistent pattern was reported across all subgroups for any of these measures. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Type 2 Diabetes Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been told you have "impaired glucose tolerance" (a condition where blood sugar is higher than normal but not yet diabetes) and are not taking any diabetes medication, OR you have Type 2 diabetes and are being treated with one or more specific diabetes medications (such as metformin alone, metformin combined with other tablets, or at least two daily insulin injections with or without metformin).
- Your HbA1c blood sugar level (a measure of average blood sugar over recent months) is between 6.5% and 8% at your screening appointment — note this does not apply if you have impaired glucose tolerance rather than diabetes.
- You are between 18 and 74 years old (inclusive), of any sex.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have Type 1 diabetes, or your diabetes was caused by a pancreas injury or another underlying condition.
- You have, or have had, an active lung disease such as tuberculosis or a fungal lung infection (confirm with trial site for the full definition used).
- You currently have, or are suspected of having, an active or returning bacterial, fungal, or viral infection at the time of joining the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 3 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Mean Change in Meal Stimulated Insulin Secretion Rate (ISR) Relative to Glucose 0-2 Hours, From Baseline to 4 Weeks.
Other options
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.